Case Investigations

Becton, Dickinson and Company

February 6, 2020 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Becton, Dickinson and Company (“Becton Dickinson” or the “Company”) (NYSE: BDX).  Investors who purchased Becton Dickinson securities may be affected.

Westpac Banking Corporation

February 4, 2020 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating Westpac Banking Corporation (“Westpac” or the “Company”) (NYSE: WBK).  A class action securities lawsuit has been filed on behalf of investors who purchased Westpac securities, including Westpac American Depositary Receipts (“ADRs”), between November 11, 2015 and November 19, 2019, inclusive (the “Class Period”).

Grand Canyon Education, Inc.

January 29, 2020 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Grand Canyon Education, Inc. (“Grand Canyon”, “GCE” or the “Company”) (NASDAQ: LOPE).  Investors who purchased Grand Canyon securities may be affected.

Qudian, Inc.

January 28, 2020 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Qudian Inc. (“Qudian” or the “Company”) (NYSE: QD).  A class action securities lawsuit has been filed on behalf of investors who purchased Qudian securities between December 13, 2018 and January 15, 2020, inclusive (the “Class Period”).

The Boeing Company

January 24, 2020 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating potential breaches of fiduciary duty claims against the board of directors of The Boeing Company (“Boeing” or the “Company”).

Harsco Corporation

January 24, 2020 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Harsco Corporation (“Harsco or the “Company”) (NYSE: HSC).  Investors who purchased Harsco common stock may be affected.

Interface, Inc.

January 23, 2020– Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Interface, Inc. (“Interface or “Company”) (NASDAQ: TILE).  Investors who purchased Interface securities may be affected.

Yext, Inc.

December 9, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Yext, Inc. (“Yext” or the “Company”) (NYSE: YEXT), a Search Experience Cloud company.

Elastic N.V.

December 9, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Elastic N.V. (“Elastic or the “Company”) (NYSE: ESTC), a data analytics provider.

Brooks Automation, Inc.

December 4, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Brooks Automation, Inc. (“Brooks Automation” or the “Company”) (NASDAQ: BRKS).

BJ's Wholesale Club

November 21, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors who purchased shares of BJ’s Wholesale Club Holdings, Inc. (“BJ’s” or the “Company”) (NYSE: BJ).

Monolithic Power Systems, Inc.

October 10, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Monolithic Power Systems, Inc. (“Monolithic” or the “Company”) (Nasdaq: MPWR).

James River Group Holdings, Ltd.

October 9, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of James River Group Holdings, Ltd. (“James River” or the “Company”) (NASDAQ: JRVR).

Jumia Technologies AG

October 8, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased American Depository Shares of Jumia Technologies AG (“Jumia” or the “Company”) (NYSE: JMIA), a pan-African e-commerce platform which connects sellers with consumers.

Minerva Neurosciences, Inc.

October 1, 2019 – Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) has been investigating claims on behalf of investors who purchased shares of Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders.